Cardiff, UK – June 18th 2012 – Two leading global IVD businesses will be sharing the stage for the first time at the American Association for Clinical Chemistry’s Annual Meeting and Clinical Lab Expo (AACC 2012). EKF Diagnostics, and AACC regulars Stanbio Laboratory (Boerne, Texas), will be exhibiting the EKF Diagnostics Group’s range of IVD products, which has expanded since Stanbio became part of EKF Diagnostics in June 2011.
At booth 1631, EKF Diagnostics will be premiering to the US market the Quo-Test and Quo-Lab glycated haemoglobin (HbA1c) analysers for near-patient measurement and monitoring of diabetes. Quo-Test, EKF Diagnostics’s flagship analyser, is accurate, simple to use and delivers results in less than four minutes, making it ideal for the physician’s office. These industry-leading qualities have ensured that more than 1,000 units are already in use globally. Quo-Lab is specifically designed for developing markets, and uses the same methodology as Quo-Test within an even more compact casing. The four-step testing procedure makes it a very cost effective option for small laboratories and diabetes clinics.
Stanbio Laboratory will focus on the Stanbio Beta-Hydroxybutyrate LiquiColor® (?-HB) Reagent System, which measures the main ketone produced during ketosis. As it provides quantitative results, unlike traditional testing methods, ?-HB is changing the way hospitals manage patients displaying symptoms of diabetic ketoacidosis. The liquid-stable reagent can be used on open channel analysers from almost twenty different manufacturers.
To highlight the use of the Beta-Hydroxybutyrate LiquiColor® Reagent System, Stanbio Laboratory and EKF Diagnostics are hosting a symposium entitled, “The value, efficacy and efficiency of Beta-Hydroxybutyrate”. This will be presented by renowned point-of-care expert, Dr James Nichols, Professor of Pathology at Tufts University School of Medicine, Boston, and Medical Director of Clinical Chemistry for Baystate Health in Springfield, Massachusetts. Dr Nichols will discuss the relative merits of the various methods of testing for diabetic ketoacidosis, including ?-HB. The free symposium will take place at 11.30 am on Wednesday July 18th at the Westin Bonaventure Hotel, Los Angeles (15 minutes’ walk from the LA Convention Centre). Early reservation via firstname.lastname@example.org is recommended as seating is limited.
According to Julian Baines, Group CEO, “AACC Clinical Lab Expo is the first time we have showcased the full range of in vitro diagnostic products within the EKF Diagnostics portfolio. Our experts will be on hand to show delegates how our innovative and high-quality products in clinical chemistry and near-patient testing are improving patient outcomes by providing practitioners with fast and accurate results, which in turn allow them to make critical decisions.”
For more information please visit www.ekfdiagnostics.com and www.stanbio.com.
About EKF Diagnostics Holdings plc
The EKF Diagnostics Group has expertise across the entire in vitro diagnostics chain, from fermentation and enzyme production, to the manufacture of liquid reagents, the design and building of world-class diagnostic devices and the distribution of rapid test kits for infectious diseases and pregnancy. The EKF range of analysers are a trusted brand in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for the measurement of glucose, lactate, haemoglobin, haematocrit and HbA1c.
To date, the EKF Diagnostics has distributors in more than 70 locations around the globe. EKF Diagnostics’ strengths lie in its multi-national research and manufacturing facilities, teams of experienced analysts and engineers in Germany, Ireland, USA and the UK, and a board led by some of world’s foremost authorities in medical diagnostics.
EKF Diagnostics Holdings plc includes wholly owned subsidiaries including Quotient Diagnostics Limited, Argutus Medical and Stanbio Laboratory. Stanbio Laboratory (Boerne, Texas) is a fifty year old business with a heritage in clinical chemistry. It was acquired in June 2011 as part of EKF’s strategy to grow its presence in North, Central and South America.